Primary Care Clinics in Park Hills, MO Accepting Medicare
8 Primary Care Clinics found. Showing 1 - 8
 Great Mines Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 116 Rebel Dr Rm 201, Park Hills, MO 63601 Phone: 573-431-2616 |
West County High School Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 768 Highway M Rm 200, Park Hills, MO 63601 Phone: 573-438-9355 |
Great Mines Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 403 W Fite St Rm 201, Park Hills, MO 63601 Phone: 573-431-2616 |
Great Mines Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 801 Columbia St Rm 216, Park Hills, MO 63601 Phone: 573-431-2616 |
Great Mines Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 412 W Fite St Rm 5, Park Hills, MO 63601 Phone: 573-438-9355 |
Great Mines Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 625 Chariton Ave Rm 103, Park Hills, MO 63601 Phone: 573-438-9355 Fax: 573-438-7892 |
West County Middle School Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 728 Highway M Rm 113, Park Hills, MO 63601 Phone: 573-438-9355 |
Great Mines Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 900 Saint Francois Ave Rm A9, Park Hills, MO 63601 Phone: 573-431-2616 |
News Archive
Esteya system for high precision skin cancer treatment gets FDA clearance
Esteya, an electronic brachytherapy system, has received 510(k) clearance from the U.S. Food and Drug Administration, enabling medical centers in the United States to offer their patients with skin cancer a new treatment option.
Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies
A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics such as small interfering RNA specifically to cancer cells.
Pulse oximetry to detect birth defects: Doctors propose nationwide screening
According to a recommendation by a federal advisory panel, before newborns leave the hospital, they should receive a simple, pain-free test to check for signs of congenital heart disease, one of the most common types of birth defects.
Gore REDUCE Clinical Study investigates PFO in stroke patients
W. L. Gore & Associates today joined the US principal investigators for the Gore REDUCE Clinical Study in reaffirming their commitment to the study of Patent Foramen Ovale (PFO) in stroke patients using the GORE HELEX Septal Occluder.
Enrollment complete in REPRISE I clinical trial for Lotus Aortic Valve System
Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
› Verified 5 days ago